Soldiering Through Scrutiny, Nu Skin Launches Growth Plan For China
This article was originally published in The Rose Sheet
Executive Summary
Nu Skin aims to achieve “higher levels of penetration” in China by expanding its direct-selling platform to additional provinces and tripling the number of stores and sales centers it operates by 2017. Meanwhile, short-seller Citron Research directs FDA and FTC to advertising for Nu Skin’s ageLOC line, which it asserts is rife with “unsubstantiated medical claims.”
You may also be interested in...
In Brief
To consider new data, Europe’s Scientific Committee on Consumer Safety plans to take another look at the safety of parabens in cosmetic products. More news in brief.
FDA Warns Lancome For Gene/Stem-Cell Claims: A Signal To Marketplace?
Claims for L’Oreal’s Lancome brand’s Genifique anti-aging line identify the products as drugs, FDA says. The agency cites claims that the brand’s technology “boosts the activity of genes” and “has been shown to improve the condition” around stem cells – language not unique in the anti-aging cosmeceutical market.
Nu Skin Unfazed By Allegations Of China Violations, Projects More Growth
Following allegations from short seller Citron Research that it operates an illegal “pyramid compensation scheme” in China, Nu Skin gives investors a peek into its business model. The firm recorded sales growth of 40% in its second quarter, driven by a 152% jump in China, and “the best is yet to come,” Nu Skin says.